VivoSeq
Oncology

Bladder Tumor

22

Pipeline Programs↗

0

Active Trials↗

14

Companies Involved↗

Bladder Tumor is an emerging landscape with 22 programs across 14 companies. The most active players are Pfizer, Eastern Cooperative Oncology Group, EMD Serono. 7 therapies are approved with 5 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

47/100

Pipeline Velocity

0/100

Mech. Concentration

15/100

Completion Rate

50/100

Attrition Rate

43/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

2 programs

Phase 1E

Eastern Cooperative Oncology Group

1 program

Phase 2EMD Serono logo

EMD Serono

1 program

Phase 2S

San Diego Pacific Oncology & Hematology Associates

1 program

Phase 2Ipsen logo

Ipsen

1 program

Phase 2Spectrum Pharmaceuticals, Inc logo

Spectrum Pharmaceuticals, Inc

2 programs

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

76%

Small molecule

16 of 21 classified programs — the dominant modality here.

24%ALL OTHERSMonoclonal antibody524%

Small molecule leads; the ring shows all 21 classified programs, each share of the total. Modality classified for 100% of 22 pipeline programs.

Analysis

Trial Status

7

clinical trials

Terminated3 · 43%
Completed3 · 43%
Unknown status1 · 14%

Clinical Trials

Trial Activity

7 trials

Safety, Dose Tolerance, Pharmacokinetics, Pharmacodynamics of CPX-POM in Patients With Newly Diagnosed or Recurrent Bladder Tumors
Completed·CCicloMed LLC·Phase 2·NCT04525131·12 enrolled
URO-BCG-4 : Bladder Tumors Immunotherapy
Completed·UUniversity Hospital, Rouen·N/A·NCT00213655·146 enrolled
Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors
Completed·—·Phase 2·NCT02197897·15 enrolled
Detection of Bladder Tumors After 30 Min Instillation of Hexvix
Terminated·PPhotocure·Phase 2·NCT01551407·38 enrolled
A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Participants Undergoing Transurethral Resection of Bladder Tumor (TURBT)
Terminated·Spectrum Pharmaceuticals, Inc logoSpectrum Pharmaceuticals, Inc·Phase 3·NCT03224182·118 enrolled
A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing Transurethral Resection Bladder Tumor (TURBT)
Terminated·Spectrum Pharmaceuticals, Inc logoSpectrum Pharmaceuticals, Inc·Phase 3·NCT02563561·62 enrolled
Perioperative Intravesical Instilation of Hypertonic Saline Following Bladder Tumor Resection
Unknown status·—·Phase 1·NCT04147182·15 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)